IX1:FRA
IDEXX Laboratories Inc
€474.60
arrow_upward
+2.04%(+9.50) 1D
Aug 24, 8:09:50 AM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IX1...
Open
€474.60
High
€474.60
Low
€474.60
Mkt. cap
44.08B
Avg. vol.
17.00
Volume
0.00
52-wk high
€665.80
52-wk low
€450.10
No. of employees
11K
Open
€474.60
High
€474.60
Low
€474.60
Mkt. cap
44.08B
Avg. vol.
17.00
Volume
0.00
52-wk high
€665.80
52-wk low
€450.10
No. of employees
11K
News stories
From web sources and news partners
DirectorsTalk Interviews
·
10 hours ago
IDEXX Laboratories, Inc. (IDXX) Stock Report: Analyzing a 25.50% Potential Upside for Savvy Investors
Ad-hoc-news.de
·
3 days ago
IDEXX Laboratories stock holds high valuation as earnings outlook firms
Yahoo Finance
·
3 days ago
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
Profile
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions.
In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO.
In 2025, IDEXX estimated annual sales between $4.21 billion and $4.28 billion, with total quarterly revenue exceeding $1 billion. Wikipedia
About IDEXX Laboratories Inc
CEOJay Mazelsky
Employees11K
FoundedDec 19, 1983
HeadquartersWestbrook, Maine, United States
SectorMedical device
Websiteidexx.com
AI content may include mistakes. Learn more